June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Identification of Common Systemic Comorbidities in Patients with Panuveitis
Author Affiliations & Notes
  • Sunil Bellur
    Ophthalmology, George Washington University Medical Faculty Associates, Washington, District of Columbia, United States
  • Haig Pakhchanian
    The George Washington University, Washington, District of Columbia, United States
  • Rahul Raiker
    West Virginia University Health Sciences Center, Morgantown, West Virginia, United States
  • Masumi Asahi
    Ophthalmology, George Washington University Medical Faculty Associates, Washington, District of Columbia, United States
  • Chloe T.L. Khoo
    Ophthalmology, George Washington University Medical Faculty Associates, Washington, District of Columbia, United States
  • H Nida Sen
    National Eye Institute, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Sunil Bellur, None; Haig Pakhchanian, None; Rahul Raiker, None; Masumi Asahi, None; Chloe Khoo, None; H Nida Sen, None
  • Footnotes
    Support  Richard A. Falls Virginia Lions Eye Institute Foundation Research Grant
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1441. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sunil Bellur, Haig Pakhchanian, Rahul Raiker, Masumi Asahi, Chloe T.L. Khoo, H Nida Sen; Identification of Common Systemic Comorbidities in Patients with Panuveitis. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1441.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : While the ocular comorbidities of panuveitis are well documented, there is a dearth of literature analyzing the general health of these patients as represented by other systemic comorbidities. This investigation identifies the fifteen most common non-ocular comorbidities in patients with panuveitis.

Methods : TriNetX (Cambridge, MA, USA) is a real-time, federated healthcare database that was used in this study. At the time of the study, the database included 60 million unique electronic medical records (EMR) of patients from 41 healthcare organizations (HCOs). The TriNetX platform mostly receives EMR data from HCO’s that are large academic centers across the USA. All data, when appropriate, were queried based on the International Classification of Diseases codes. The goal of this study was to analyze the prevalence of non-ocular comorbidities amongst panuveitis patients in this cohort. Inclusion criteria included patients with ICD-10 codes corresponding to panuveitis (H44.11) and the fifteen most prevalent ICD-10 codes associated with a disease diagnosis. Patients aged 18 years and older were included.

Results : 6126 patients with panuveitis were identified in the cohort. The mean age +/- standard deviation was 52.7 +/- 18.4 years old. 57% of the cohort was female (n=3490) and 43% male (n=2633). 52% of the study population identified as white (n=3219), 27% black or African American (n=1647), and 3% as Asian (n=158). The fifteen most common systemic comorbidities included essential hypertension 14% (n=1141), disorders of lipoprotein metabolism and other lipidemias 11.6% (n=712), diabetes mellitus 10.5% (n=647), other diseases of intestines 9.5% (n=584), gastroesophageal reflux disease 8.7% (n=535), benign neoplasms 7.7% (n=476), osteoarthritis 7.5% (n=464), nicotine dependence 7.3% (n=448), other headache syndromes 7.3% (n=445), major depressive disorder 7.1% (n=437), obesity 6.9% (n=428), anemia unspecified 6.6% (n=407), inflammatory polyarthropathies 6.5% (n=309), sleep disorders 6.3% (n=384), and other anxiety disorders 6.1% (n=374).

Conclusions : To our knowledge this is the first study looking at the prevalence of non-ocular comorbidities in panuveitis patients. Further research is necessary to determine which comorbidities are more prevalent than in the general population and which are possible secondary effects from therapies.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×